Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
18.47
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hutchmed China Ltd ADR
< Previous
1
2
3
4
5
6
7
8
Next >
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
February 06, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
February 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2023 Final Results
February 01, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
January 29, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
January 10, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
December 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
November 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
November 24, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
November 10, 2023
Via
Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
November 10, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 08, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
November 08, 2023
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.
Via
Investor's Business Daily
Rocket Pharmaceuticals Stock Sees Improved Price Strength
November 02, 2023
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78
Via
Investor's Business Daily
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
November 01, 2023
Virtual Investor Conference on November 8th and 9th, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
October 27, 2023
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
October 27, 2023
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
October 24, 2023
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
October 16, 2023
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
October 16, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday
October 11, 2023
U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sarepta Therapeutics Stock Showing Rising Relative Strength
October 09, 2023
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
September 29, 2023
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
September 28, 2023
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Via
Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
September 27, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
September 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
September 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.